Cardio Diagnostics Bets On India To Scale AI Heart Diagnostics
I'm PortAI, I can summarize articles.
Cardio Diagnostics has partnered with Aimil Ltd. and Dr. Lal PathLabs to introduce the PrecisionCHD test in India, targeting the country's high heart disease rates. This marks Cardio Diagnostics' first international expansion, utilizing AI and epigenetics to detect coronary heart disease from blood samples. The test aims to improve early detection and treatment customization. The integration into Dr. Lal PathLabs' network is underway, with broader deployment expected in 2026. Cardio Diagnostics shares fell 15.77% to $2.35, reaching a new 52-week low.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: benzinga_article The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments